Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia

References

• Hoelzer D, Thiel E, Löffler H, Büchner T, Gansner A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123–131
   PubMed Web of Science ®Google Scholar
• Larson R A, Dodge R K, Bums C P, Lee E J, Stone R M, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85: 2025–2037
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Smith T L, Cortes J, Giles F J, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561
   PubMed Web of Science ®Google Scholar
• Petersdorf S H, Kopecky K J, Head D R, Boldt D H, Balcerzak S P, Wun T, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia 2001; 15: 208–216
   PubMed Web of Science ®Google Scholar
• Annino L, Vegan M L, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL0288 randomized study. Blood 2002; 99: 863–871
   PubMed Web of Science ®Google Scholar
• Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464–2471
   PubMed Web of Science ®Google Scholar
• Hunault M, Harousseau J L, Delain M, Truchan-Graczyk M, Cahn J Y, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after high-dose therapy and autologous BMT. a GOELAMS trial. Blood 2004; 104: 3028–3037
   PubMed Web of Science ®Google Scholar
• Rowe J M, Buck G, Burnett A K, Chopra R, Wiemik P H, Richards S M, et al. Induction therapy for adult acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XIII/ECOG E2993. Blood 2005; 106: 3760–3767
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron J M, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter S, Ludwig W D, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM90. German-Austrian-Swiss ALL BFM Study Group. Blood 2000; 95: 3310–3322
   PubMed Web of Science ®Google Scholar
• Silverman L B, Gelber R D, Dalton V K, Asselin B L, Barr R D, Clavell L A, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Faber consortium protocol 91-01. Blood 2001; 97: 1211–1218
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Bassan R, Lerede T, Rambaldi A, Di Bona E, Rossi G, Pogliani E, et al. The role of anthracyclines in adult acute lymphoblastic leukemia. Leukemia 1996; 10(Suppl 2)S58–S61
   PubMed Web of Science ®Google Scholar
• Bassan R, Battista R, D'Emilio A, Viero P, Dragone P, Dini E, et al. Long-term results of the HEAV'D protocol for adult acute lymphoblastic leukaemia. Eur J Cancer 1991; 27: 441–447
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Richards S M, Lazarus H M, Tallman M S, Buck G, Fielding A K, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833
   PubMed Web of Science ®Google Scholar
• Secker-Walker L M, Prentice H G, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trial UKALL XA-MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 601–610
   PubMed Web of Science ®Google Scholar
• Wetzler M, Dodge R K, Mrosek K, Carroll A J, Tantravahi R, Block A W, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999; 93: 3983–3993
   PubMed Web of Science ®Google Scholar
• Gleißner B, Gökbuget N, Bartram C R, Janssen B, Rieder H, Janssen J WG, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536–1543
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, Beelen D W, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006; 108: 1469–1477
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugimura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460–466
   PubMed Web of Science ®Google Scholar
• Delannoy A, Delabesse E, Lheritier V, Castaigne S, Rigal-Huguet F, Raffoux E, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20: 1526–1532
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc M F, Lheritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780
   PubMed Web of Science ®Google Scholar
• Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K, et al. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: ALL-90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998; 68: 279–289
   PubMed Web of Science ®Google Scholar
• Hatta Y, Takeuchi J, Ohshima T, Horikoshi A, Iizuka Y, Kawamura M, et al. Analysis of 20-year follow-up study of LVP regimen for adult acute lymphoblastic leukemia. Int J Hematol 2001; 74: 157–164
   PubMed Web of Science ®Google Scholar
• Ng S M, Lin H P, Ariffin W A, Zainab A K, Lam S K, Chan L L. Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol. J Trop Pediatr 2000; 46: 338–343
   PubMed Web of Science ®Google Scholar
• Bassan R, Lerede T, Rambaldi A, Di Bona E, Rossi G, Pogliani E, et al. The role of anthracyclines in adult acute lymphoblastic leukaemia. Leukemia 1996; 10(Suppl 2)S58–S61
   PubMed Web of Science ®Google Scholar